Design Therapeutics (DSGN) closed at $10.77 on November 11, 2026, up 1.1% from the previous close, on volume of 440,902 shares (30-day average 439,497).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Market Chameleon (Mon, 18-May 3:28 AM ET)
Market Chameleon (Wed, 29-Apr 6:33 AM ET)
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Design Therapeutics trades on the NASDAQ stock market under the symbol DSGN.
As of November 12, 2026, DSGN stock price declined to $10.55 with 138,505 million shares trading.
DSGN has a beta of 1.43, meaning it tends to be more sensitive to market movements. DSGN has a correlation of 0.09 to the broad based SPY ETF.
DSGN has a market cap of $658.76 million. This is considered a Small Cap stock.
In the last 3 years, DSGN traded as high as $17.25 and as low as $1.99.
The top ETF exchange traded funds that DSGN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
DSGN has outperformed the market in the last year with a return of +36.0%, while the SPY ETF gained +12.4%. However, in the most recent history, DSGN shares have underperformed the stock market with its stock returning -27.8% in the last 3 month period and -4.8% for the last 2 week period, while SPY has returned -1.1% and -1.6%, respectively.
DSGN support price is $10.31 and resistance is $11.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DSGN shares will trade within this expected range on the day.
